# Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Canonical URL: https://biopharmsignal.com/news/LGVN/longeveron-to-report-2025-full-year-financial-results-and-host-conference-call-o-17f05ec3
Ticker: LGVN
Company: Longeveron
Source: Longeveron
Published: 2026-03-12 13:00 EST
## Summary

Longeveron to report 2025 full year financial results and provide a business update on March 17, 2026 after the U.S. financial markets close. ...

## Article Body
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

| Conference Call Number: | 1.877.407.0789 |
| --- | --- |
| Conference ID: | 13758462 |
| Call me TM Feature: | Click Here |
| Webcast: | Click Here |

An archived replay of the webcast will be available on the “ Events & Presentations ” section of the Company’s website following the conference.

About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B ® ), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn , X , and Instagram .

Investor and Media Contact: Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com
## Recent Company News
- 2026-07-23 13:15 EST — [Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors](https://biopharmsignal.com/news/LGVN/deborah-d-ascheim-m-d-elected-to-longeveron-board-of-directors-86a5bee6) — Source: Longeveron
- 2026-07-13 11:05 EST — [Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease](https://biopharmsignal.com/news/LGVN/longeveron-announces-presentation-of-clinical-data-at-the-2026-alzheimer-s-assoc-50c3353b) — Source: Longeveron
- 2026-07-06 20:05 EST — [Longeveron® Appoints Marie Washburn as Chief Financial Officer](https://biopharmsignal.com/news/LGVN/longeveron-appoints-marie-washburn-as-chief-financial-officer-510c9ad9) — Source: Longeveron
- 2026-06-18 13:20 EST — [New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)](https://biopharmsignal.com/news/LGVN/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-a-7acdaf6c) — Source: Longeveron
- 2026-06-09 13:20 EST — [Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)](https://biopharmsignal.com/news/LGVN/longeveron-granted-small-or-medium-sized-enterprise-sme-status-by-the-european-m-25b20fb2) — Source: Longeveron
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)